A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection.

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs LTX 109 (Primary)
  • Indications Gram-positive infections; Skin infections
  • Focus Adverse reactions
  • Sponsors Lytix Biopharma
  • Most Recent Events

    • 27 Apr 2012 Planned number of patients changed from 24 to 35 as reported by European Clinical Trials Database record.
    • 15 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Actual initiation date (September 2010), official title, lead investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top